A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial

Autor:	Gottfried E. Konecny, Diane Provencher, Noa Ben-Baruch, Jalid Sehouli, Paul Cottu, Chen Wang, Gabriele Feisel, Sylvie Jacod, Fritz Jänicke, Hsiao-Wang Chen, Beth Y. Karlan, Lynda D. Roman, Martin Pölcher, Paul Haluska, Vincent Houe, Matthias W. Beckmann, Judy Dering, Dennis J. Slamon, Isabelle Ray-Coquard, Achim Rody
Rok vydání:	2014
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Placebo-controlled study Front line medicine.disease Placebo Carboplatin/paclitaxel Surgery Double blind Internal medicine Medicine business Ovarian cancer
Zdroj:	Journal of Clinical Oncology. 32:5529-5529
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2014.32.15_suppl.5529
Popis:	5529 Background: IGF signaling has been implicated in the pathogenesis and progression of ovarian cancer (OC). Ganitumab (GAN; AMG 479) is an investigational, fully human, monoclonal antibody inhib...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::95ddb28b6b9cf067401584938882ef48 https://doi.org/10.1200/jco.2014.32.15_suppl.5529 Zobrazit plný text záznamu